Hjertemagnyl It is used in the following conditions:
Prevention of thrombosis in patients with ischemic heart disease, myocardial infarction, ischemic stroke or transient ischemic attack (attack of circulatory disorders).
It blocks the aggregation (adhesion) of platelets (platelets) and is used to reduce the risk of clots forming from the platelets.
– The active substance is acetylsalicylic acid. Each film-coated tablet contains 150 mg of acetylsalicylic acid.
– The other ingredients in the tablet core are magnesium hydroxide, potato starch, magnesium stearate, maize starch, microcrystalline cellulose. The other ingredients in the film are hypromellose, propylene glycol and talc.
How to use
Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. If you are not sure, talk to your doctor or pharmacist.
The recommended dose for adults is 75 to 150 mg (one tablet) once a day. If a dose of less than 150 mg is required, tablets of a different strength should be used.
In some conditions, the dose may be increased, but only if your doctor tells you to.
The tablet should be swallowed with a glass of water. The tablet can be swallowed whole. It can be divided into two parts or chewed to make it easier to swallow.
Use in children and adolescents
Hjertemagnyl should not be used in children and adolescents under 16 years of age.
Hjertemagnyl is not for use in children aged 16 to 18 years.
Talk to your doctor before use.
Patients with renal
impairment No dose adjustment is required for patients with mild to moderate renal impairment, but caution should be exercised. Do not use in patients with severe renal impairment.
Patients with hepatic
impairment No dose adjustment is required for patients with mild to moderate hepatic impairment, but caution should be exercised. Do not use in patients with severe hepatic impairment.